Cytori Cell Research Institute, Inc. stock analysis
Want to see JP:3750 full AI Analyst Report?
Cytori Cell Research Institute, Inc. (3750) Stock Price & Analysis
3750 Stock Chart & Stats
- Day’s Range
- JPY 785.00 - JPY 815.00
- 52-Week Range
- JPY 743.00 - JPY 890.00
- Previous Close
- JPY 777.00
- Volume
- N/A
- Average Volume (3M)
- 5,173
- Market Cap
- JPY 6.94B
- Enterprise Value
- JPY 7.13B
- Total Cash (Recent Filing)
- JPY 67.10M
- Total Debt (Recent Filing)
- JPY 250.00M
- Price to Earnings (P/E)
- ―
- Beta
- 0.42
- Next Earnings
- Feb 05, 2027 (Est.)
- EPS Estimate
- N/A
- Last Dividend Ex-Date
- Mar 30, 2020
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Gross Margin Recovery
The return to positive gross margin indicates that the underlying products or services generated some contribution above direct costs. If sustained, this could provide a base for recovery, although operating expenses currently overwhelm gross profit.
Reported Debt Reduction
The disappearance of reported debt may reduce interest and refinancing pressure and improve financial flexibility. However, the benefit is constrained by the company’s sharply reduced equity base and continuing operating losses.
Reduced Cash Burn Versus Prior Year
The smaller absolute free-cash-flow outflow suggests some improvement in cash consumption compared with the prior year. This is a limited positive because operations remain materially cash-negative and the business is not yet self-funding.
Bears Say
Severe Revenue Contraction
The sustained collapse in revenue indicates substantial deterioration in commercial scale, product demand, or business activity. A smaller revenue base makes it harder to absorb fixed costs and rebuild profitability over the next several periods.
Deep Operating Losses
Extremely negative operating and net margins show that overhead and other costs vastly exceed gross profit. Unless the company materially restructures expenses or expands revenue, persistent losses will continue eroding financial resilience.
Weak Balance Sheet And Cash Generation
Ongoing cash burn combined with a near-depleted equity cushion leaves limited capacity to absorb further losses. Even with zero reported debt, the company may remain dependent on financing or restructuring to sustain operations.
3750 FAQ
What was Cytori Cell Research Institute, Inc.’s price range in the past 12 months?
What is Cytori Cell Research Institute, Inc.’s market cap?
When is Cytori Cell Research Institute, Inc.’s upcoming earnings report date?
How were Cytori Cell Research Institute, Inc.’s earnings last quarter?
Is Cytori Cell Research Institute, Inc. overvalued?
Does Cytori Cell Research Institute, Inc. pay dividends?
What is Cytori Cell Research Institute, Inc.’s EPS estimate?
How many shares outstanding does Cytori Cell Research Institute, Inc. have?
What happened to Cytori Cell Research Institute, Inc.’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Cytori Cell Research Institute, Inc.?
What is the TipRanks Smart Score and how is it calculated?
Company Description
Cytori Cell Research Institute, Inc.
Operating from its Tokyo headquarters, Cytori Cell Research Institute, Inc., established in 2004 (originally FRACTALE Corporation), specializes in the comprehensive research, development, production, and distribution of medical devices related to cell therapy throughout Japan. The company offers various cell therapy kits and continuously advances cellular treatment technologies through ongoing research and development. Its active development pipeline includes ECCI-50, designed for the treatment of male stress urinary incontinence and hepatic cirrhosis, and Cyt-006, formulated to prevent postoperative adhesion after primary rectal cancer surgery. Additionally, Cytori conducts extensive clinical trials and investigations into cell-based therapies for a wide array of conditions and applications, such as the repair of anterior cruciate ligaments and bones, burn scar remediation, chronic wound healing, critical limb ischemia, treatment of anal and Crohn's disease fistulas, and erectile dysfunction. Beyond its primary biotechnological focus, the company also participates in the real estate sector, encompassing investment, ownership, development, leasing, and management of properties and hotels, as well as providing real estate brokerage services.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Yoshihiro Hoshino
- Employees
- 13
- Website
- adr.co.jp
- Address
- FDC Kojimachi Building, Tokyo, TY, 102-0083, JP
Cytori Cell Research Institute, Inc. (3750) Earnings & Revenues
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 13 | 5 | 4 |
| Technical Analysis | 3 | 5 | 2 |
| Moving Averages | 10 | 0 | 2 |

